KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 7

Prognostic factors and outcome of ABVD chemotherapy in childhood Hodgkin Iymphoma: A single center experience

Hüseyin Murat MUTUŞ
Mustafa Asım YÖRÜK
Gunes FEYİZOGLU
Çetin TİMUR
Sayfa
1258–1263
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Presence of bulky disease, nodular sclerosing histologic subtype andleukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The aim was to analyze the outcome of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine,and dacarbazine (ABVD) chemotherapy + adjuvant radiotherapy according to the risk groups and determine the adverse prognosticfactors affecting survival in Hodgkin lymphoma.Material and Methods: A retrospective study was performed on 52 pediatric patients with Hodgkin lymphoma who were treated withABVD between 1997 and 2018.
📊
Temel Bulgular & Veri:Patients with early-stage favorable disease received 4 cycles of ABVD + radiotherapy.
💡
Sonuç & Katkı:Presence of bulky disease, nodular sclerosing histologic subtype andleukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: The aim was to analyze the outcome of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vinblastine,and dacarbazine (ABVD) chemotherapy + adjuvant radiotherapy according to the risk groups and determine the adverse prognosticfactors affecting survival in Hodgkin lymphoma.Material and Methods: A retrospective study was performed on 52 pediatric patients with Hodgkin lymphoma who were treated withABVD between 1997 and 2018. Patients with early-stage favorable disease received 4 cycles of ABVD + radiotherapy. Early-stageunfavorable and advanced-stage patients received 6 cycles of ABVD + radiotherapy.Results: Thirty (57.7%) boys and 22 (42.3%) girls were included in the study. The median age of the patients was 9 years and 3months (1 year and 10 month – 17 years and 7 months). Overall survival rate was 94.2% and the mean survival time was 19.5±0.70(95% CI, 18.1 - 20.9) years. The mean event-free survival time was 9.5±6.5 years. Overall survival rate was 90%, and the meanevent-free survival time was 8.2±6.1 years in early-stage favorable disease. Overall survival rate was 100%, and the mean eventfreesurvival time was 1.9±7.0 years in early-stage unfavorable disease. Overall survival rate was 94.1 %, and the mean event-freesurvival time was 8.9±6.3 years in advanced-stage disease. Presence of bulky disease, nodular sclerosing histologic subtype andleukocytosis had a negative prognostic effect on relapse and bulky disease had adverse effect on overall survival (p

🔖

Bu Makaleye Atıf Yap

MUTUŞ, H. M., YÖRÜK, M. A., FEYİZOGLU, G., TİMUR, Ç. (2022). Prognostic factors and outcome of ABVD chemotherapy in childhood Hodgkin Iymphoma: A single center experience. Annals of Medical Research, Cilt: 26 - Sayı: 7, 1258–1263. https://ajindex.com/articles/446819

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Bonadonna G, Viviani S, Bonfante V, et al. Survival in Hodgkin’s disease patients - report of 25 years of experience at the milan cancer institute. Eur J Cancer 2005;41:998- 1006
  2. Meyer RM, Gospodarowicz MK, Connors JM, et al: NCIC Clinical trials group; eastern cooperative oncology group. abvd alone versus radiation-based therapy in limited-stage hodgkin’s lymphoma. N Engl J Med 2012;366:399-408
  3. Viviani S, Bonadonna G, Santoro A, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin’s disease: ten-year results. J Clin Oncol 1996;14:1421-30
  4. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003;21:607-14
  5. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684-91
  6. Chisesi T, Bellei M, Luminari S, et al. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin’s lymphoma: a study from the Intergruppo Italiano Linfomi. J Clin Oncol 2011;29:4227-33
  7. Carde P, Karrasch M, Fortpied C, et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016;34:2028-36
  8. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:1622-8
  9. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:640-52
  10. Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin’s Disease: Multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000;6:1150-60
  11. Celkan T, Baris S, Ozkan A, ve ark. Çocukluk çağı Hodgkin lenfomanın seyri ile hematolojik ve diğer değişkenlerin ilişkisi Turk Arch Ped 2008;43:46-9
  12. Garcia R, Hernandez JM, Caballero MD, et al. Serum lactate dehydrogenase level as a progno